JAMJOOM PHARMACEUTICALS COMPANY FACTORY

The GCC pharmaceutical market, led by Saudi Arabia, is rapidly expanding due to factors like population growth and lifestyle diseases. The market is expected to exceed US$ 12 Billion by 2030, with branded and imported drugs dominating. Clinical trials in the region involve over 250 drugs, and healthcare transformation programs are driving growth. Local manufacturing is increasing, especially in generics and biosimilars, while digital health innovations are enhancing market efficiency.

The GCC pharmaceutical market is rapidly expanding, led by Saudi Arabia, with a projected value over US$ 12 Billion by 2030. Growth is fueled by population increase, lifestyle diseases, and healthcare investments. Local manufacturing and digital health integration are rising, alongside a growing generics market. Regulatory developments support market evolution towards greater sophistication.